Studies on quinolone antibacterials. V. Synthesis and antibacterial activity of chiral 5-amino-7-(4-substituted-3-amino-1-pyrrolidinyl)-6- fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acids and derivatives

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 7, 1996, Pages 1376-1386

  Yoshida, Toshihiko ^a   Yamamoto, Yoichi ^a   Orita, Hitomi ^a   Kakiuchi, Masato ^a   Takahashi, Yoshie ^a   Itakura, Masakazu ^a   Kado, Noriyuki ^a   Yasuda, Shingo ^a   Kato, Hideo ^a   Itoh, Yasuo ^a  

^a Abbott Japan Co Ltd   (Japan)

Author keywords

5 amino 8 methylquinolone; antibacterial activity; convulsive activity; DNA gyrase; DNA topoisomerase II; phototoxicity

Indexed keywords

5 AMINO 7 (3 AMINO 4 METHYL 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; 5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FELBINAC; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CONVULSION; DOSE RESPONSE; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GUINEA PIG; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHOTOTOXICITY;

EID: 0008821147     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.1376     Document Type: Article

References (31)

1. Part IV: Yoshida T., Yamamoto Y., Orita H., Kakiuchi M., Takahashi Y., Itakura M., Kado N., Mitani K., Yasuda S., Kato H., Itoh Y., Chem. Pharm. Bull., 44, 1074-1085 (1996).
2. Wise R., Andrews J. M., Edwards L. J., Antimicrob. Agents Chemother., 23, 559-564 (1983).
3. Hayakawa I., Hiramitsu T., Tanaka Y., Chem. Pharm. Bull., 32, 4907-4913 (1984).
4. Ueda Y., Shimizu K., Konno M., Matsumoto F. (ed.), "The Quinolones," Life Science Publisher, Tokyo. 1991, pp. 1-14.
5. a) Narita H., Konishi Y., Nitta J., Kitayama I., Miyajima M., Watanabe Y., Yotsuji A., Saikawa I., Yakugaku Zasshi, 106. 802-807 (1986);
6. b) Rosen T., Chu D. T. W., Lico I. M., Fernandes P. B., Shen L., Borodkin S., Pernet A. G., J. Med. Chem., 31, 1586-1590 (1988).
7. Sanchez J. P., Domagala J. M., Hagen S. E., Heifetz C. L., Hutt M. P., Nichols J. B., J. Med. Chem., 31, 983-991 (1988).
8. a) Itoh Y., Kato H., Ogawa N., Koshinaka E., Suzuki T., Ger. Offen. Patent 3433924 (1985) [Chem. Abstr., 103, 123517b (1985)];
9. b) Okezaki E., Terasaki T., Nakamura M., Nagata O., Kato H., Tsuji A., Drug Metab. Dispos., 16, 856-874 (1988).
10. Miyamoto T., Matsumoto J., Chiba K., Egawa H., Shibamori K., Minamida A., Nishimura Y., Okada H., Kataoka M., Fujita M., Hirose T., Nakano J., J. Med. Chem., 33, 1645-1656 (1990).
11. a) Yoshida T., Takeshita M., Orita H., Kado N., Yasuda S., Kato H., Itoh Y., Chem. Pharm. Bull., 44, 1128-1131 (1996);
12. b) Di Cesare P., Bouzard D., Essiz M., Jacquet J. P., Ledoussal B., Kiechel J. R., Remuzon P., Kessler R. E., Fung-Tomc J., J. Med. Chem., 35, 4205-4213 (1992);
13. c) Asahina Y., Fukuda Y., Fukuda H., European Patent 443498 (1990) [Chem. Abstr., 115, 256018j (1991)];
14. d) Hirabayashi S., Ike K., Zanka A., Kawakami T., Ichihara M., World Intellectual Property Organization 9220652 (1992) [Chem. Abstr., 119, 180649a (1993)];
15. e) Kimura Y., Atarashi S., Kawakami K., Sato K., Hayakawa I., J. Med. Chem., 37, 3344-3352 (1994);
16. f) Ito Y., Kato H., Yasuda S., Kato N., Yoshida T., Ueshima M., Japan Kokai Tokkyo Koho, Japan. Paient 05345777 (1994) [Chem. Abstr., 120, 298485t (1994)];
17. g) Okada T., Sato H., Tsuji T., Tsushima T., Nakai H., Yoshida T., Matsuura S., Chem. Pharm. Bull., 41, 132-138 (1993).
18. Matsumoto J., Miyamoto K., Egawa H., Nakamura S., Japan Kokai Tokkyo Koho, Japan. Patent 61137885 (1986) [Chem Abstr., 106, 4996j (1987)].
19. Sanchez J. P., Domagala J. M., Heifetz C. L., Priebe S. R., Sesnie J. A., Trehan A. K., J. Med. Chem., 35, 1764-1773 (1992).
20. Hagen S. E., Domagala J. M., Heifetz C. L., Sanchez J. P., Solomon M., J. Med. Chem., 33, 849-854 (1990).
21. Ohta M., Koga H., J. Med. Chem., 34, 131-139 (1991).
22. 14C-HSR-903) had a good absorption and high biliary excretion. These results will be reported elsewhere.
23. Ueda Y., Shimizu K., Konno M., Matsumoto F., (ed.), "The Quinolones," Life Science Publisher, Tokyo 1991. pp. 275-286.
24. a) Ueda Y., Shimizu K., Konno M., Matsumoto F., (ed.), "The Quinolones," Life Science Publisher, Tokyo 1991, pp. 315-326;
25. b) Akahane K., Sekiguchi M., Une T., Osada Y., Antimicrob. Agents Chemother., 33, 1704-1708 (1989).
26. Goto S., Jo K., Kawakita T., Kosakai N., Mitsuhasi S., Nishino T., Ohsawa N., Tanami H., Chemotherapy, 29, 76-79 (1981).
27. Bliss C. I., Method Probit. Science, 79, 38-39 (1934).
28. Satou E., Katumura Y., Itikawa H., Kobayasi T., Nakazimu K., Nishinihon Hifuka, 42, 831-837 (1980).
29. Heaulme M., Chambon J. P., Leyris R., Wermuth C. G., Biziere K., J. Neurochem., 48, 1677-1686 (1987).
30. Otter R., Cozzarelli N. R., Methods Enzymol., 100, 171-180 (1983).
31. Manual for Topoisomerase II Drug Screening Kit by Topo GEN. Inc.